SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event

Loading news article.

SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event | WAPE

SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event

Article summary

Related companies

Comments —